Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Formurx Pharmaceuticals Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, SHOMER, ISAAC, who holds the 1 busiest examiner pending action. The prosecution is currently limited to 1 distinct art unit, reflecting a focused approach to the company's pending intellectual property. The 1 pending office action represents the entirety of the company's current activity at the USPTO.
Since SHOMER, ISAAC is the only examiner involved, the success of the prosecution depends on addressing his specific concerns. The 1 distinct art unit involved indicates that the Biotechnology & Pharmaceuticals claims are not being reviewed by multiple technical divisions, allowing for a streamlined response strategy. Practitioners can focus their efforts on the 1 busiest examiner pending action without the complexity of managing multiple examiners. This concentrated prosecution environment under 1 distinct examiner simplifies the administrative and legal requirements for the company's current patent application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.1% | +30.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697939 | Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids | SHOMER, ISAAC | 164d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17697939 | Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids | SHOMER, ISAAC | 1612 | §103 | Non-Final OA | 164d overdue | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFormurx Pharmaceuticals Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Isaac Shomer has the most, with 1 of Formurx Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.